Association between antidiabetic drugs and the incidence of atrial fibrillation in patients with type 2 diabetes: A nationwide cohort study in South Korea
Authors' conclusion
The combination therapy of MET and TZD is the most effective antidiabetic drug for preventing AF in patients with type 2 diabetes.
Study context
- Population
- Patients with T2D without history of atrial fibrillation (AF) who underwent health check-ups 2009–2012, Korea; mean age 62 ± 11 years, 60 % men89,125 new AF
- Participants
- 2,515,468 patients
- Exposure
- Antidiabetic drug combinations vs no medication
- Outcome
- Newly diagnosed AF incidence
- Follow-up
- Until December 2018
Methodological detailsKorean National Insurance Service database
- Korean National Insurance Service database
Main finding
As reported in the abstract
Newly diagnosed AF
Each group vs no medicationHazard ratio (95 % CI)
MET
0.959(0.935–0.985)
- Metformin (MET) combination therapy
- HR < 1
- MET (adjusted) HR
- 0.977 (95 % CI 0.964-0.99)
- Thiazolidinedione (TZD) (adjusted) HR
- 0.926 (95 % CI 0.898-0.956)
- MET + TZD combination therapy HR; more remarkable than other combinations
- 0.802 (95 % CI 0.754-0.853)
Observational data: associations, not effects.
Further findings
Subgroups (age, sex, duration, diabetes severity)
- Preventive effect of MET and TZD against AF remained consistent across subgroups
Original publication
Association between antidiabetic drugs and the incidence of atrial fibrillation in patients with type 2 diabetes: A nationwide cohort study in South Korea. Diabetes Res Clin Pract. Published 16 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →